Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Danaher Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $157.3B | |
|---|---|---|
| Revenue (ttm) | 25.6B | |
| Net income (ttm) | 4.3B | |
| EPS (ttm) | $6.10 | |
| Shares out | 703.5M | |
| P/E (trailing) | 38.3x | |
| P/E (forward) | 23.8x | |
| Dividend | $1.60 (0.68%) | |
| Volume | 2,725,890 | |
| Beta | 0.80 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $24.80B | $26.64B | $23.89B | $23.88B | $24.57B | -0.2% |
| Gross profit | $15.24B | $16.19B | $14.03B | $14.21B | $14.52B | -1.2% |
| Operating income | $6.38B | $7.54B | $5.20B | $4.86B | $4.69B | -7.4% |
| Net income | $6.43B | $7.21B | $4.76B | $3.90B | $3.61B | -13.4% |
| EPS (diluted) | $8.61 | $9.66 | $6.38 | $5.29 | $5.05 | -12.5% |
| EBITDA | $10.01B | $9.49B | $5.20B | $7.28B | $6.95B | -8.7% |
| R&D | $1.50B | $1.53B | $1.50B | $1.58B | $1.60B | +1.6% |
| SG&A | $6.82B | $7.12B | $7.33B | $7.76B | $8.24B | +4.8% |
Recent company headlines from major financial publishers.
Consolidated core revenue expands at 3%-4% in FY2026 and reaccelerates to 8.0% in FY2027 as customer batch manufacturing schedules normalize and deferred chromatography resin shipments deliver,. Operating margins progress from 19.09% in FY2025 to 26.5% in FY2026 and reach 28.5% over the forecast horizon,. Free cash flow conversion remains above 100%, funding debt service and regular share repurchases.
Rapid absorption of bioprocessing inventory leads to accelerated commercial batch manufacturing and new greenfield quoting. Specialty diagnostics maintain high single-digit momentum driven by DxI 9000 and Cepheid non-respiratory assays, while China hospital procurement rebounds. Operating margins expand ahead of schedule, driving strong double-digit earnings growth.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 7.5% | $207 | $212 | $217 | $224 | $231 |
| 8.0% | $192 | $196 | $201 | $205 | $211 |
| 8.5% | $180 | $183 | $187 | $190 | $194 |
| 9.0% | $170 | $172 | $175 | $178 | $181 |
| 9.5% | $161 | $163 | $165 | $167 | $170 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
